Q32 Bio Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QTTB research report →
Range $14 – $66
Price Chart
About the company
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation.
- CEO
- Jodie Pope Morrison
- IPO
- 2018
- Employees
- 22
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on QTTB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $249.57M
- P/E
- 2.66
- Fwd P/E
- 47.01
- PEG
- 0.01
- P/S
- 4.64
- P/B
- 0.99
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
- Gross Margin
- 99.84%
- Op Margin
- 34.20%
- Net Margin
- 60.02%
- ROE
- 26.77%
- ROIC
- 6.28%
Latest fiscal year · YoY change
- Revenue
- $53.74M+0.0%
- Gross Profit
- $53.74M+0.0%
- Op Income
- $16.90M
- Net Income
- $29.82M+162.5%
- EPS
- $2.42+147.3%
- OCF Growth
- +50.5%
- FCF Growth
- +50.5%
- 52W High
- $23.57
- 52W Low
- $1.93
- 50D MA
- $8.98
- 200D MA
- $9.58
- Beta
- -0.33
- RSI (14)
- 43
- Avg Volume
- 690.47K
No earnings-call transcripts are available for QTTB yet.
- Free Float
- 44.9%
- Shares Outstanding
- 29.92M
- Float Shares
- 13.45M
of shares held by institutions
73 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Orbimed Advisors LLC | 4.13M | ▲ 1.88M |
| Boxer Capital Management, LLC | 3.15M | ▲ 3.15M |
| Atlas Venture Life Science Advisors, LLC | 2.72M | 0 |
| Bvf Inc/Il | 2.35M | ▲ 2.35M |
| Ra Capital Management, L.P. | 2.33M | ▲ 2.33M |
| Point72 Asset Management, L.P. | 1.17M | ▲ 1.17M |
| Jpmorgan Chase & Co | 1.06M | ▲ 1.06M |
| Vanguard Capital Management LLC | 1.01M | ▲ 489.65K |
| Opaleye Management Inc. | 931.00K | ▼ 325.23K |
| Logos Global Management LP | 800.00K | ▲ 800.00K |
| Summittx Capital, L.P. | 733.77K | ▲ 733.77K |
| American Century Companies Inc | 652.60K | ▲ 379.85K |
Held by 44 ETFs
Biggest fund positions in QTTB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Morrison Jodie Pope | sell | 3,221 |
| Oct 6, 26 | Kalowski Lee | sell | 1,301 |
| Oct 6, 26 | Violette Shelia M. | sell | 917 |
| Aug 25, 26 | Morrison Jodie Pope | sell | 9,845 |
| Aug 25, 26 | Kalowski Lee | sell | 3,972 |
| Aug 25, 26 | Violette Shelia M. | sell | 2,798 |
| Jun 12, 26 | TZIANABOS ARTHUR | other | 10,826 |
| Jun 12, 26 | Lundberg Sven Ante | other | 10,826 |
| Jun 12, 26 | LAPORTE KATHLEEN | other | 10,826 |
| Jun 12, 26 | Iwicki Mark T | other | 10,826 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QTTB coverage
Recent articles, reports, and earnings notes.
No research on QTTB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QTTB report →Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 11
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com · Nov 4
Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)
defenseworld.net · Oct 12
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
prnewswire.com · Sep 30
Q32 Bio: Durable Hair Regrowth Remains The Goal
seekingalpha.com · Sep 26
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
prnewswire.com · Sep 21
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 15
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.
prnewswire.com · Sep 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.